Helix BioPharma Shareholders Overwhelmingly Approve All Meeting Items

Helix BioPharma Corp., a clinical-stage oncology company trading on the TSX, OTC, and FWB exchanges under symbols HBP, HBPCF, and HBP0, has announced overwhelmingly positive voting results from its Annual General and Special Meeting held on January 30, 2026. Shareholders demonstrated strong support, with 81.03% of total issued and outstanding shares represented at the meeting. All items of business were approved with near-unanimous votes of 99.99%, including the re-election of four director nominees—Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube—as detailed in the company's Management Information Circular dated December 15, 2025. Additional approvals included appointing Clearhouse LLP as auditor and authorizing a share consolidation of up to five pre-consolidation shares for one post-consolidation share, with the board determining the final ratio. A comprehensive report on all voting matters will be filed on SEDAR+, accessible at www.sedarplus.com, ensuring transparency for investors and stakeholders.

The company, headquartered in Toronto with CEO Thomas Mehrling at the helm, is focused on developing innovative therapies for hard-to-treat cancers through its proprietary bio-conjugate technology platform. Helix's pipeline is led by its clinical-stage candidate, Tumour Defence Breaker™ L-DOS47, an antibody-enzyme conjugate that targets CEACAM6-expressing solid tumors like non-small cell lung cancer (NSCLC). This therapy aims to neutralize tumor microenvironments and enhance anti-cancer immunity, potentially complementing existing treatments. The voting results reflect shareholder confidence in Helix's strategic direction and leadership, as the company continues to advance its oncology research and development efforts. For more details, investors can visit the company's website at https://www.helixbiopharma.com/ or refer to the original release on www.newmediawire.com, which provides further context on the meeting outcomes.

In the broader context, Helix BioPharma's progress is underscored by its commitment to tackling urgent cancer challenges, with forward-looking statements highlighting ongoing clinical trials and potential partnerships. However, the company acknowledges risks such as financing uncertainties, regulatory hurdles, and trial delays, as outlined in its annual reports on SEDAR+. The strong shareholder support at the meeting signals optimism in Helix's ability to navigate these challenges and deliver on its promise of vincible cancer treatments. This news not only impacts current investors but also positions Helix as a key player in the oncology sector, with implications for future healthcare innovations and patient outcomes. The integration of anchor text keywords like Management Information Circular and www.sedarplus.com emphasizes the importance of regulatory compliance and investor access to detailed information.